https://www.selleckchem.com/pr....oducts/lonafarnib-sc
Canagliflozin reduced the risk of kidney failure and related outcomes in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) in the CREDENCE trial. This analysis of CREDENCE trial data examines the effect of canagliflozin on the incidence of kidney-related adverse events (AEs). A randomized, double-blind, placebo-controlled, multicenter, international trial. 4,401 trial participants with T2DM, CKD, and urinary albumincreatinine ratio 300-5000mg/g. Participants were randomly assigned to receive
Like
Comment
Share
